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In multiple sclerosis (MS), compromised blood-brain barrier (BBB) integrity contributes to inﬂammatory T cell migration
into the central nervous system. Matrix metalloproteinase-9 (MMP-9) is associated with BBB disruption and subsequent T cell
migration into the CNS. The aim of this paper was to evaluate the eﬀects of omega-3 fatty acids on MMP-9 levels and T cell
migration. Peripheral blood mononuclear cells (PBMC) from healthy controls were pretreated with two types of omega-3 fatty
acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Cell supernatants were used to determine MMP-9 protein
and activity levels. Jurkat cells were pretreated with EPA and DHA and were added to ﬁbronectin-coated transwells to measure T
cell migration. EPA and DHA signiﬁcantly decreased MMP-9 protein levels, MMP-9 activity, and signiﬁcantly inhibited human T
cell migration. The data suggest that omega-3 fatty acids may beneﬁt patients with multiple sclerosis by modulating immune cell
production of MMP-9.
1.Introduction
Multiplesclerosis(MS)isaninﬂammatorydiseaseofthecen-
tral nervous system (CNS) in which T-lymphocytes, macro-
phages, and antibodies are believed to be involved in de-
myelination and axonal damage [1–3]. Although the cause
ofMSisunknown,thereisgeneralagreementthatMSresults
from an acquired immune-dysregulation and aberrant acti-
vation leading to T cell-driven inﬂammatory processes in the
CNS that result in demyelination and axonal damage. MS
disease modifying therapies act by altering the T cell-driven
inﬂammatory processes in the CNS [4–10]. Given that these
therapies are only partially eﬀective, there is still a need to
identify novel therapies that are eﬀective and safe.
Matrix metalloproteinase-9 (MMP-9) is one member
in a family of proteases that aid in the remodeling of the
extracellular matrix, basement membrane, and other tissues
in the body by digesting collagen components in these tis-
sues. In MS, MMP-9 is thought to have a signiﬁcant role
in the transmigration of inﬂammatory cells into the CNS
by aiding in the disruption of the blood brain barrier [11].
Several studies have reported higher MMP-9 levels in MS
subjects when compared to control subjects [12–15]. Inter-
feron beta (IFN-beta) has the ability to inhibit MMP-9 levels
produced from T-lymphocytes and CD4+ T cells [16–18],
which is thought to be one mechanism by which this therapy
acts to alter the disease course [17].
Eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) are two forms of long-chain omega-3 fatty acids
(omega-3 FA) that are immune cell modulators and have
been reported to decrease proinﬂammatory cytokine levels
secreted from stimulated PBMC from patients with MS [19].
Omega-3 FA are reported to signiﬁcantly decrease levels of
MMP-2, -3, -9, and -13 [20–22]. One in vitro study reports
a dose-dependent decrease in MMP-9 protein levels secreted
from LPS-activated microglial cells that were incubated with
either ﬁsh oil or an omega-3 FA mixture (53% EPA and 27%
DHA) [23]. Reported data on the ability of EPA and DHA
to decrease proinﬂammatory cytokine and MMP-9 levels
suggest a potential therapeutic role for these omega-3 FA in2 Autoimmune Diseases
MS. Our group observed a signiﬁcant decrease in MMP-9
p r o t e i ns e c r e t e df r o mu n s t i m u l a t e dP B M Ci na no p e n - l a b e l
study of ten relapsing remitting MS patients [24].
T h eo b j e c t i v e so ft h ei nv i t r os t u d yw e r e( 1 )t oe v a l u a t e
diﬀerent concentrations of EPA and DHA on MMP-9 pro-
tein levels secreted from PBMC, (2) to evaluate diﬀerent
concentrations of EPA and DHA on MMP-9 activity secreted
from PBMC, and (3) to evaluate diﬀerent concentrations of
EPA and DHA on the migration of human T cells across a
ﬁbronectin barrier.
2.Methods and Materials
2.1. Subjects. This study was approved by the Oregon
Health & Science University’s Institutional Review Board
and subjects gave consent before having their blood drawn.
Thirteen healthy control subjects were enrolled for a single
blood draw for PBMC isolation. Inclusion criteria included
subjectsthatwereage18yearsorolderwithnoserioushealth
condition (e.g., neurologic disorder, cardiovascular disease,
uncontrolleddiabetes,andcancer).Exclusioncriteriainclud-
ed any one of the following: pregnancy, omega-3 FA sup-
plementation within 4 weeks of blood draw, eating one serv-
ing of ﬁsh per week within 4 weeks of blood draw, and
daily use of prescription or over the counter anti-inﬂam-
matory medication within two weeks of blood draw. PBMC
were isolated from the heparinized blood of healthy control
subjects within 4 hours of blood draw (Lymphocyte Separa-
tion media; Mediatech).
2.2. PBMC Incubation with EPA and DHA. PBMC were
resuspended in X-Vivo 15 supplemented with 1% L-gluta-
mine, 100U/mL penicillin, 100ug/mL streptomycin, 1% so-
dium pyruvate, and 25mM HEPES at 2×106 cells/mL. Fatty
acids to be used for in vitro incubations were prepared
based on the method of Curtis et al. [20]. Brieﬂy, fatty acid
free albumin (Sigma-Aldrich) was resuspended at a con-
centration of 3.5μg/mL in Tyrode-HEPES buﬀer (20mM
HEPES, 140mM NaCl, 4.5mM KCl, 1mM MgCl2,2 . 5m M
CaCl2, 11mM glucose, pH 7.4). EPA, DHA, and oleic acid
(OA) were obtained from Sigma-Aldrich and were made up
in this buﬀer as a stock solution of 5mg/mL, incubated for
16hr at 37◦C with rotation, sterilized, and stored for up to 1
week at −20◦C.
After separation, PBMC were pretreated for 2 hours with
EPA and DHA at the following concentrations: 10μg/mL,
25μg/mL, and 50μg/mL, followed by stimulation with con-
canavalin A (ConA). Cell supernatants were collected to de-
termine MMP-9 levels and MMP-9 activity. Oleic acid (OA)
is a monounsaturated fatty acid and served as an oil con-
trol. Control PBMC were incubated with OA for 2 hours
at the following concentrations: 10μg/mL, 25μg/mL, and
50μg/mL, followed by stimulation with ConA. Untreated
PBMC that were stimulated with ConA served as the refer-
ence control (deﬁned as 100% MMP-9 activity).
2.3. Measurement of MMP-9 Levels and MMP-9 Activity.
MMP-9levelsweremeasuredbyenzyme-linkedimmunosor-
bent assay (R&D Systems Inc, Minneapolis, MN). MMP-9
activity from cell supernatants was determined by gelatin
substrate zymography [25].
2.4. Jurkat Cell Culture and Transmigration Assay. Ah u m a n
CD4+ T cell line (Jurkat clone E6-1; ATCC) was chosen for
the transmigration assays as CD4+ T cells are implicated in
MS pathogenesis. These assays were based on those previ-
ously described by our laboratory [25]. Jurkat cell cultures
were grown in RPMI 1640 supplemented with 10% heat-
inactivated fetal bovine serum, 2mM L-glutamine, penicil-
lin-streptomycin (100U/mL and 100μg/mL, resp.), 1mM
sodium bicarbonate, 25mM HEPES at 37◦C and 5% CO2.
Cells were added to 3μm ﬁbronectin-coated transwells
(VWR International, Bridgeport, NJ) at 2 × 106 cells per mL
in 200μL 1% FBS medium. 600μL of medium alone was
added to the lower chambers. EPA was added at 10, 30,
and 100μg/mL, DHA at 10, 30, and 100μg/mL, and control
wells were incubated with OA at 30μg/mL. All reagents were
added in equal ﬁnal concentrations to both upper and lower
chambers. Migration was carried out for 20 hours at 37◦C.
Plates were then shaken for 10 minutes to remove adherent
cells from the bottom of the transwells. Transwells were re-
moved and Calcein AM was added at a ﬁnal concentration
of 50mM and cells were incubated at 37◦Cf o r4 5m i n u t e s .
Fluorescence was read on a Cytoﬂuor 4000 (485λ excitation,
535λ emission). Transmigration assays were performed three
separate times; values from a representative experiment are
expressedasapercentageofcellﬂuorescenceofsaline-treated
wells.
2.5. Data Analysis. Data from three diﬀerent healthy control
subjects with identical experimental conditions were ana-
lyzed. Statistical analysis was performed using SPSS version
14.0. Migratory capacity of untreated control cells, expressed
aspercentageofCalceinAM-positivecellsinthelowercham-
ber, was deﬁned as 100%; migratory capacity of cells incu-
bated with varying concentrations of DHA, EPA, and OA
werecalculatedasapercentageofthe controlwells.Similarly,
the percentage of MMP-9 activity following treatment with
varyingconcentrationsofDHA,EPA,andOAwereexpressed
as a percentage relative to the untreated control (deﬁned as
100%). ANOVA was used to compare MMP-9 protein levels
and percent activity. Tukey’s HSD was used to compare the
diﬀerencebetweeneachconcentrationofDHA,EPA,andOA
totheuntreatedcontrol.Standarderror(SE)wasdetermined
from the standard deviation (SD) derived from the means of
the three healthy controls for each omega-3 concentration
(SD/
√
3). T-test was used to compare percent activity and
percent migration of each concentration compared to the
untreated control. Signiﬁcance was deﬁned as P ≤ 0.05.
3. Results
3.1. Omega-3 FA Eﬀects on PBMC Secreted MMP-9 Levels.
Figure 1 shows the eﬀects of DHA, EPA, and the oil control
OA on MMP-9 protein levels. DHA at 10μg/mL decreased
mean MMP-9 levels to 85.5ng/mL (SE ± 10.9; P = 1.0),
at 25μg/mL decreased mean MMP-9 levels to 41.5ng/mLAutoimmune Diseases 3
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Figure 1: Mean MMP-9 protein levels secreted from PBMC. PBMC
from three diﬀerent normal controls. MMP-9 levels secreted from
ConA-stimulated PBMC is decreased following treatment with
DHA and EPA when compared to an untreated ConA-stimulated
PBMC control. OA served as an oil control and showed no sig-
nificantdecreaseinMMP-9levelsatanyconcentration.PBMCwere
pretreated for 2hr in the presence of 10, 25, and 50μg/mL of one
of the following, DHA, EPA, or OA. Cells were then stimulated
with ConA and supernatants were collected to determine MMP-9
levelsbyELISA.Errorbarsrepresentstandarderror(SE). ∗Signiﬁcant
decrease compared to control (P ≤ 0.05).
(SE ±7.5;P = 0.29),andat50μg/mLdeceasedMMP-9levels
to non-detectable (P = 0.05). EPA at 10μg/mL decreased
mean MMP-9 levels to 50.9ng/mL (SE ± 9.2; P = 0.61), at
25μg/mL decreased mean MMP-9 levels to 4.4ng/mL (SE ±
4.4; P = 0.05), and at 50μg/mL decreased MMP-9 levels to
non-detectable (P = 0.04). There was no signiﬁcant decrease
in MMP-9 levels for any of the OA concentrations (P = 1.0
for all concentrations).
3.2. Omega-3 Eﬀects on PBMC Secreted MMP-9 Activity.
Figure 2 shows the eﬀect of DHA, EPA, and OA on mean
MMP-9 activity. DHA at 10μg/mL decreased mean MMP-9
activityby21.5%(SE ±8.0;P = 0.57),at25μg/mLdecreased
mean MMP-9 activity by 29.0% (SE ± 7.5; P = 0.34), and at
50μg/mL decreased mean MMP-9 activity to by 51.4% (SE
± 20.1; P = 0.05). EPA at 10μg/mL decreased mean MMP-9
activity by 9.6% (SE ± 6.0; P = 0.91), at 25μg/mL decreased
mean MMP-9 activity by 29.0% (SE ± 11.0) (P = 0.28), and
at 50μg/mL decreased mean MMP-9 activity by 69.0% (SE
± 11.0; P = 0.007). OA at 10μg/mL decreased mean activity
to 9.0% (SE ± 6.0; P = 0.90), at 25μg/mL decreased mean
activity by 14.6% (SE ± 13.0; P = 0.71), and at 50μg/mL
decreased mean activity by 29.0% (SE ± 13.0; P = 0.21).
3.3. Jurkat Cell Migration Assay. Coincubation of human
Jurkat T cells with DHA and EPA reduced their migratory
capacityacrossapseudo-bloodbrainbarrierinadosedepen-
dent manner (Figures 3(a) and 3(b)). DHA at 30μg/mL
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Figure 2: Mean MMP-9 activity from PBMC supernatants.
PBMC from three diﬀerent normal controls. MMP-9 activity from
supernatants of ConA-stimulated PBMC is decreased following
treatment with DHA and EPA when compared to an untreated
ConA-stimulated PBMC control (100% MMP-9 activity). OA
served as an oil control and showed no signiﬁcant decrease in
MMP-9 levels at any concentration. PBMC were pretreated for 2hr
in the presence of 10, 25, and 50μg/mL of one of the following,
DHA, EPA, or OA. Cells were then stimulated with ConA and
supernatants were collected to determine MMP-9 activity by gelatin
substrate zymography. Error bars represent SE. ∗Signiﬁcant decrease
compared to control (P ≤ 0.05).
reduced Jurkat cell migration by 46.2% and at 100μg/mL by
83.9% (P ≤ 0.05 for both). Culture supernatants collect-
ed at the end of the migration period were subjected to
electrophoresis and gelatin substrate zymography to assess
MMP-9 activity. Corresponding to the eﬀect on migratory
capacity, DHA at 30μg/mL reduced MMP-9 activity by
36.3% and at 100μg/mL by 97.6% [P<0.05 for both;
Figure 3(a)]. Similarly, EPA treatment of Jurkat cell cultures
signiﬁcantly reduced the ability of Jurkat cells to cross a
ﬁbronectin barrier with a corresponding reduction in MMP-
9a c t i v i t y .E P Aa t1 0μg/mL reduced Jurkat cell migration by
46.9%, at 30μg/mL by 51.8%, and at 100μg/mL by 83.1%
(P ≤ 0.05 for all). EPA at 30μg/mL reduced MMP-9 activity
by 69.6% and at 100μg/mL by 88.3% [P ≤ 0.05 for both;
Figure 3(b)]. OA (oil control) at 30μg/mL reduced Jurkat
cell migration by 5.5% (P = 0.66), MMP-9 activity was not
assessed in cells treated with OA.
4. Discussion
The study shows that DHA and EPA, individually and at low
in vitro concentrations, have the ability to decrease MMP-9
production and activity in PBMC from healthy controls. In
addition,bothtypesofomega-3FAwereabletoinhibitTcell
migration through a ﬁbronectin barrier in a concentration-
dependent fashion. Cell viability was checked for all in vitro
assays and remained between 68–84% for all concentrations4 Autoimmune Diseases
Control 10 30 100 OA (30)
0
20
40
60
80
100
0
20
40
60
80
100
M
i
g
r
a
t
i
o
n
(
%
)
A
c
t
i
v
i
t
y
(
%
)
Treatment (µg/mL)
Migration (%)
Activity (%)
∗
∗
(a) DHA eﬀect on Jurkat cell migration and MMP-9 Activity
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(b) EPA eﬀect on Jurkat cell migration and MMP-9 Activity
Figure 3: Jurkat cell migration is decreased following treatment with DHA or EPA when compared to an untreated control (100%
migration). MMP-9 activity from Jurkat cell supernatants is decreased following treatment with DHA or EPA when compared to an
untreated control (100% activity). Supernatants were collected from the cultures undergoing migration to determine MMP-9 activity by
gelatin substrate zymography. Jurkat cells were incubated for 20hr in the presence of 10, 30, and 100μg/mL of DHA or EPA. OA (30μg/mL)
served as an oil control for cell migration. Migration assays were performed three separate times, representative data is displayed. ∗Signiﬁcant
decrease in migration compared to control (P ≤ 0.05). ∗∗Signiﬁcant decrease in Jurkat cell migration and MMP-9 activity compared to
control (P ≤ 0.05).
tested, indicating that the eﬀects observed were not a result
of cell death.
MMP-9-mediated disruption of the blood brain barrier
is one mechanism in which inﬂammatory cells enter the
CNS in MS. MS patients are reported to have signiﬁcantly
elevated MMP-9 mRNA levels when compared to healthy
controls. The increased MMP-9 expression in immune cells
(PBMC) may enable these cells to more readily migrate
across the blood brain barrier and enter the CNS [26, 27].
St¨ uve et al. observed that activated T-lymphocytes isolated
f r o mu n t r e a t e dM Sp a t i e n t sw e r ea b l et om i g r a t et h r o u g h
a ﬁbronectin barrier due to increased MMP-9 activity. T-
lymphocytes treated with IFN-beta decreased the migratory
ability of these cells [18]. Dressel et al. observed that the mi-
gration of CD4+ T cells through a ﬁbronectin barrier, but
notCD8+cells,wasenhancedinuntreatedMSpatientscom-
pared with controls and that CD4+ cell migration and
MMP-9 production were reduced by IFN-beta treatment
[16]. Decreasing MMP-9 expression and MMP-9 protein
levels in T-lymphocytes is one proposed mechanism for the
therapeutic action of IFN-beta therapy in MS [17].
In the present study, we demonstrated that EPA and
DHAwereabletodecreaseMMP-9proteinlevelsandactivity
at relatively low concentrations. Incubation of PBMC from
healthy controls with DHA and EPA at 50μg/mL reduced
MMP-9 levels to non-detectable levels and reduced MMP-
9 activity by 51% and 69%, respectively. Oleic acid, a
monounsaturated fatty acid, served as an oil control and did
not signiﬁcantly decrease MMP-9 level or activity (Figures 1
and 2). In addition, EPA at as low as 10μg/famL and DHA
at 30μg/mL signiﬁcantly inhibited T cell migration through
a ﬁbronectin barrier and this inhibition was associated with
decreased MMP-9 activity [Figures3(a) and 3(b)]. Oleic acid
did not signiﬁcantly inhibit T cell migration. These ﬁndings
indicate that the omega-3 FA, DHA and EPA, have the ability
to decrease immune cell secretion of MMP-9 protein and
reduce its activity; together, these modulatory eﬀects on
MMP-9 may impede cell migration across the basement
membrane of the CNS.
Mean Cmax levels in plasma are reported at 7.7mg/dL
for EPA and 9.8mg/dL for DHA after supplementation with
ﬁsh oil at a daily oral dose of 3.0 grams (containing 0.57
grams EPA and 0.45 grams DHA) [28]. In the present study,
the in vitro concentration of EPA and DHA at 5mg/dL
(50μg/mL) showed a decrease in MMP-9 levels, activity, and
a decrease in T cell migration. The results presented sug-
gest that it may be possible to decrease MMP-9 levels at a
dose of omega-3 FA that is one-third of the dose reported to
d ecr easeMMP -9lev elsinMSs ubjects[24].Therearelimited
studiesevaluatingtheeﬀectsofomega-3FAsupplementation
in MS and only one study evaluating omega-3 FA eﬀects
on MS disease activity. One double-blind placebo-controlled
trial that randomized MS patients (n = 312) to 20 ﬁsh oil
capsules/day or an olive oil placebo reported a trend in im-
provement in the ﬁsh-oil-treated subjects compared to con-
trols in disease severity (Expanded Disability Status Scale)
over 2 years (P = 0.07) [29]. The olive oil placebo contained
72%oleicacid,andtheﬁshoilcontainedEPA1.71grams/day
and DHA 1.41 grams/day. One study reported a signiﬁcant
decrease from baseline in the levels of the proinﬂammatory
cytokines Interleukin-1beta (IL-1 β)( P<0.03), tumor ne-
crosis factor-alpha (TNF-α)( P<0.02), IL-2 (P<0.002),
and IFN-γ (P<0.01), produced from unstimulated and
stimulated PBMC of MS subjects and healthy controls
supplemented with ﬁsh oil [19]. Our group has reported a
decrease in MMP-9 levels from baseline in an open labelAutoimmune Diseases 5
study of ten relapsing remitting MS patients receiving ﬁsh
oil concentrate at 8 grams/day (2.9 grams EPA and 1.9
gramsDHA)over3months.ThereducedMMP-9levelswere
observed in all ten subjects whether or not they were taking
MS disease modifying medication [24]. Drawing from the
limited clinical trial reports, there is some suggestion that
omega-3fattyacidshaveimmunomodulatorypropertiesthat
may be beneﬁcial in MS. Further exploration on the optimal
dosing of omega-3 FA in MS is needed.
5. Conclusions
The presented combined results from the in vitro study
and the open-label study in MS suggest that DHA and EPA
omega-3 FA may have a role in inhibiting the migration of
activated immune cells into the central nervous system and
that further investigation of omega-3 FA in MS is warranted.
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